Sridhar VS, et al. Chronic kidney disease in type 1 diabetes: Translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes. Diabetologia 2024; 67:3–18. doi: 10.1007/s00125-023-06015-1
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy. ClinicalTrials.gov identifier: NCT02065791. Updated December 12, 2019. https://clinicaltrials.gov/study/NCT02065791
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2022; 102:S1–S127. doi: 10.1016/j.kint.2022.06.008
Agarwal R, et al.; FIDELIO-DKD and FIGARO-DKD Investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis. Eur Heart J 2022; 43:474–484. doi: 10.1093/eurheartj/ehab777
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease. ClinicalTrials.gov identifier: NCT03819153. Updated April 30, 2024. https://clinicaltrials.gov/study/NCT03819153
ElSayed NA, et al.; on behalf of the American Diabetes Association. 10. Cardiovascular disease and risk management: Standards of care in diabetes—2023. Diabetes Care 2023; 46(Suppl 1):S158–S190. doi: 10.2337/dc23-S010
Lee JF, et al. Cardiorenal protection in diabetic kidney disease. Endocrinol Metab (Seoul) 2021; 36:256–269. doi: 10.3803/EnM.2021.987
Neuen BL, et al. Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation 2024; 149:450–462. doi: 10.1161/CIRCULATIONAHA.123.067584